Drug Trial Radar · NCT06848231
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Dasher Neuroscience Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Conditions
- Multiple System Atrophy
Interventions
YA-101Drug
Drug: YA-101 • YA-101 taken BID
PlaceboDrug
Placebo taken BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events (AEs)Time frame: Baseline to Day 112
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
UCLA Health
Los Angeles, California
Brigham and Women's Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Columbia University Irving medical center
New York, New York
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Juntendo University Hospital
Tokyo, Japan
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital Cancer Center
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.